Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 1 December 2005. doi:10.1136/ard.2005.037275
Annals of the Rheumatic Diseases 2006;65:354-359
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2005.037275v1
65/3/354    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mazières, B
Right arrow Articles by Dougados, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazières, B
Right arrow Articles by Dougados, M

EXTENDED REPORT

Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH* Cohort

B Mazières 1, P Garnero 2, A Guéguen 3, M Abbal 1, L Berdah 4, M Lequesne 5, M Nguyen 6, J-P Salles 1, E Vignon 7, M Dougados 6

1 Paul Sabatier University & Rangueil Hospital, Toulouse, France
2 Synarc, Lyon, France
3 INSERM U 88/IFR69, Paris, France
4 Negma-Lerads, Toussus-le-Noble, France
5 Leopold Bellan Hospital, Paris, France
6 Rene Descartes University and Cochin Hospital, Paris, France
7 Lyon-Sud Hospital, Pierre-Benite, France

Correspondence to:
Correspondence to:
Professor B Mazières
Department of Rheumatology CHU Rangueil 1; avenue Jean-Poulhès, Toulouse, 31059 France; mazieres{at}cict.fr

Objective: To determine whether systemic markers of bone, cartilage, and synovium can predict structural progression of osteoarthritis (OA).

Methods: Patients with painful hip OA were treated with diacerein or placebo in a multicentre, prospective, double blind, 3 year follow up trial. The following information was collected at entry: demographics, characteristics of hip OA, and 10 markers: N-propeptides of collagen types I and III, cartilage oligomeric matrix protein, YKL-40, hyaluronan (sHA), matrix metalloproteinases-1 and -3, C reactive protein, C-terminal crosslinking telopeptides of collagen types I and II (uCTX-II). Radiographs were obtained at entry and every year. Structural progression was defined as a joint space decrease >=0.5 mm or requirement for total hip replacement. Grouped survival analysis was performed with time to structural progression as dependent variable, and clinical data, radiographic findings, treatment groups (diacerein versus placebo), and markers as explanatory measures.

Results: In the 333 patients in whom all markers were measured, high functional impairment, a joint space width <2 mm, and lateral migration of the femoral head at baseline increased the risk of progression, but diacerein had a protective effect (relative risk = 0.75; 95% confidence interval (CI) 0.54 to 0.96). In addition, patients in whom uCTX-II and sHA were in the upper tertile had a relative risk of progression of 3.73 (95% CI 2.48 to 5.61) compared with patients with markers in the two lower tertiles.

Conclusion: In this large cohort, combined measurements of uCTX-II and sHA were a new predictor of the structural progression of hip OA.


Keywords: molecular markers; osteoarthritis; hips




This article has been cited by other articles:


Home page
J Bone Joint Surg BrHome page
T. C. B. Pollard, S. E. Gwilym, and A. J. Carr
The assessment of early osteoarthritis
J Bone Joint Surg Br, April 1, 2008; 90-B(4): 411 - 421.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
M. Sharif, J. Kirwan, N. Charni, L. J. Sandell, C. Whittles, and P. Garnero
A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis--association with disease progression
Rheumatology, June 1, 2007; 46(6): 938 - 943.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
B. Mazieres, M. Hucher, M. Zaim, and P. Garnero
Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study
Ann Rheum Dis, May 1, 2007; 66(5): 639 - 645.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
P. Garnero
New Biochemical Markers of Cartilage Turnover in Osteoarthritis: Recent Developments and Remaining Challenges
IBMS BoneKEy, January 1, 2007; 4(1): 7 - 18.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
P Garnero, N Charni, F Juillet, T Conrozier, and E Vignon
Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis
Ann Rheum Dis, December 1, 2006; 65(12): 1639 - 1644.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism